Celldex Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Celldex Therapeutics, Inc. (CLDX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $22.40 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-09
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $22.40M, a 12.29% decline year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $27.78M, a 48.22% increase year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $14.92M, a 21.66% increase year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $667.00K.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $68.91M.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$50.19M.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$41.01M.
- Celldex Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$77.42M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $22.40M 10-Q · filed 2017-05-09 | $50.18M derived: sum of 2 quarters · filed 2017-05-09 | $65.10M derived: sum of 3 quarters · filed 2017-05-09 | $65.77M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | $27.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $42.70M derived: sum of 2 quarters · filed 2017-03-14 | $43.37M derived: sum of 3 quarters · filed 2017-03-14 | $68.91M 10-K · filed 2017-03-14 |
| 2016-09-30 | $14.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $15.59M derived: sum of 2 quarters · filed 2016-11-07 | $41.12M 10-Q · filed 2016-11-07 | $59.87M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-06-30 | $667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $26.21M 10-Q · filed 2016-08-08 | $44.95M derived: sum of 3 quarters · filed 2017-05-09 | $57.21M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-03-31 | $25.54M 10-Q · filed 2017-05-09 | $44.28M derived: sum of 2 quarters · filed 2017-05-09 | $56.55M derived: sum of 3 quarters · filed 2017-05-09 | $40.38M derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | $18.74M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $31.01M derived: sum of 2 quarters · filed 2017-03-14 | $14.84M derived: sum of 3 quarters · filed 2017-03-14 | -$50.19M 10-K · filed 2017-03-14 |
| 2015-09-30 | $12.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$3.90M derived: sum of 2 quarters · filed 2016-11-07 | -$68.94M 10-Q · filed 2016-11-07 | -$51.24M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | -$16.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$81.20M 10-Q · filed 2016-08-08 | -$63.50M derived: sum of 3 quarters · filed 2017-03-14 | -$45.48M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | -$65.03M 10-Q · filed 2016-05-05 | -$47.34M derived: sum of 2 quarters · filed 2017-03-14 | -$29.32M derived: sum of 3 quarters · filed 2017-03-14 | -$24.72M derived: sum of 4 quarters · filed 2017-03-14 |
| 2014-12-31 | $17.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $35.72M derived: sum of 2 quarters · filed 2017-03-14 | $40.32M derived: sum of 3 quarters · filed 2017-03-14 | -$41.01M 10-K · filed 2017-03-14 |
| 2014-09-30 | $18.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $22.62M derived: sum of 2 quarters · filed 2015-11-05 | -$58.71M 10-Q · filed 2015-11-05 | -$72.53M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$76.73M 10-Q · filed 2015-08-10 | -$90.55M derived: sum of 3 quarters · filed 2016-02-25 | -$84.99M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$81.33M 10-Q · filed 2015-04-29 | -$95.15M derived: sum of 2 quarters · filed 2016-02-25 | -$89.59M derived: sum of 3 quarters · filed 2016-02-25 | -$112.17M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | -$13.82M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-02-25 | -$8.26M derived: sum of 2 quarters · filed 2016-02-25 | -$30.84M derived: sum of 3 quarters · filed 2016-02-25 | -$77.42M 10-K/A · filed 2016-02-25 |
| 2013-09-30 | $5.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | -$17.02M derived: sum of 2 quarters · filed 2014-11-05 | -$63.60M 10-Q · filed 2014-11-05 | -$68.14M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | -$22.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$69.16M 10-Q · filed 2014-08-07 | -$73.70M derived: sum of 3 quarters · filed 2015-02-24 | -$67.71M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$46.58M 10-Q · filed 2014-05-01 | -$51.11M derived: sum of 2 quarters · filed 2015-02-24 | -$45.13M derived: sum of 3 quarters · filed 2015-02-24 | -$36.05M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | -$4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $1.45M derived: sum of 2 quarters · filed 2015-02-24 | $10.53M derived: sum of 3 quarters · filed 2015-02-24 | -$16.98M 10-K · filed 2015-02-24 |
| 2012-09-30 | $5.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $15.06M derived: sum of 2 quarters · filed 2013-11-08 | -$12.44M 10-Q · filed 2013-11-08 | -$4.40M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $9.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$18.43M 10-Q · filed 2013-08-06 | -$10.39M derived: sum of 3 quarters · filed 2014-03-03 | -$34.00K derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | -$27.51M 10-Q · filed 2013-05-03 | -$19.46M derived: sum of 2 quarters · filed 2014-03-03 | -$9.11M derived: sum of 3 quarters · filed 2014-03-03 | -$34.93M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $18.40M derived: sum of 2 quarters · filed 2014-03-03 | -$7.42M derived: sum of 3 quarters · filed 2014-03-03 | -$2.15M 10-K · filed 2014-03-03 |
| 2011-09-30 | $10.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | -$15.47M derived: sum of 2 quarters · filed 2012-11-02 | -$10.20M 10-Q · filed 2012-11-02 | -$2.69M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-06-30 | -$25.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$20.55M 10-Q · filed 2012-08-09 | -$13.04M derived: sum of 3 quarters · filed 2013-03-08 | |
| 2011-03-31 | $5.27M 10-Q · filed 2012-05-04 | $12.78M derived: sum of 2 quarters · filed 2013-03-08 | ||
| 2010-12-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | -$16.16M 10-K · filed 2013-03-08 | ||
| 2010-09-30 | -$23.67M 10-Q · filed 2011-11-03 | |||
| 2009-12-31 | $45.09M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |